Sophia Genetics Q1 2024 GAAP EPS $(0.21) Beats $(0.28) Estimate, Sales $15.779M Miss $16.467M Estimate
Sophia Genetics Q1 2024 GAAP EPS $(0.21) Beats $(0.28) Estimate, Sales $15.779M Miss $16.467M Estimate
Sophia Genetics 2024年第一季度GAAP每股收益美元（0.21）超過預期（0.28），銷售額爲1,5779萬美元，低於1646.7萬美元的預期
Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.28) by 25 percent. This is a 32.26 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $15.779 million which missed the analyst consensus estimate of $16.467 million by 4.18 percent. This is a 12.98 percent increase over sales of $13.966 million the same period last year.
索菲亞遺傳學（納斯達克股票代碼：SOPH）公佈的季度虧損爲每股0.21美元，比分析師普遍預期的0.28美元（0.28美元）高出25％。與去年同期每股虧損（0.31）美元相比，增長了32.26％。該公司公佈的季度銷售額爲157.79萬美元，比分析師普遍預期的1646.7萬美元低4.18％。這比去年同期的1,396.6萬美元的銷售額增長了12.98％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。